Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia - Test2 - elhamkhani - TriplyDB

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

http://www.wikidata.org/entity/Q28140129

about

Purine Antagonists for Chronic Lymphocytic Leukaemia Purine Antagonists for Chronic Lymphocytic Leukaemia The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia Stem cell transplantation in chronic lymphocytic leukemia Fludarabine in the treatment of chronic lymphocytic leukemia: a review Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model Covalent and Noncovalent Intermediates of an NAD Utilizing Enzyme, Human CD38 Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment Trial Watch: Proteasomal inhibitors for anticancer therapy The biology behind PI3K inhibition in chronic lymphocytic leukaemia Pentostatin in chronic lymphocytic leukemia Re-directing an alkylating agent to mitochondria alters drug target and cell death mechanism Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.An update on the management of chronic lymphocytic leukaemia.ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC.The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias.Alemtuzumab in chronic lymphocytic leukemia Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.Autoimmune thrombocytopenia due to chronic lymphocytic leukemia treated with fludarabine.Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis.Oblimersen for the treatment of patients with chronic lymphocytic leukemia.Alemtuzumab for B-cell chronic lymphocytic leukemia.Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia.

P2860

Q24245132-BECD5A6B-DCCA-482D-968C-E2994CA9A34B Q24248167-9985F402-3854-4484-B5BC-E7280B5D95CE Q24605471-0FF6A266-524A-4571-9A98-5DCE56444380 Q24617708-1CBBC47F-D6EA-4CE8-B671-B962EC94BED0 Q24642921-5AB04D25-9859-4D29-A01C-C92B79025BA0 Q24645173-D32A07A8-9F86-4E26-A6F0-4C4A2E8738F3 Q24681296-CDF9FB1D-9451-4DC1-A758-B21990C18069 Q26738934-D7B5974E-04B6-4365-A6D2-648CDE88B6B0 Q26765624-18B37480-698F-4EE2-9F3B-E48C81911451 Q26781163-9240E9DC-716E-47B6-B83E-400E696F960F Q27001163-514C682A-B284-448A-B41C-CA82CE7843DD Q27312452-3ED2C897-749E-4F2F-8771-A90D313EB3B5 Q27652605-7868DD98-D4D7-4C87-A472-974F3925A937 Q28075606-096AFDF5-E46F-4C86-A8DF-EABB60D1D73A Q28075683-411D1895-50FA-455E-BFD6-FA8FD710A8F3 Q28081162-75F44BD5-D913-4949-B5D3-E2BC0006BFB2 Q28082086-F14B3C6B-9071-4231-94C3-3BAB0CAEE51C Q28082910-1E37753F-C536-4394-970B-D3A23B3844F6 Q28083266-36EFF19C-491E-45C8-86C6-7AAC3BC69E61 Q28291531-48FEC122-4C26-4E72-8F55-C6CA400D9BA9 Q28486104-E2B06997-FEDF-4206-9E5D-101A2716D603 Q28533669-FF70C957-3D5E-4A6D-AB21-C01929349DA1 Q30243968-AB106746-5F8D-430C-A441-6A7CB77173BE Q30341946-68930AB6-8CD2-4ECC-ABA0-508A3AADDBFC Q30486336-B042617E-B023-44CA-99F1-679A1AB739B2 Q31150630-31446C6F-699D-4D53-86E5-F975ABA4CC06 Q33288974-03986EA9-112B-41AB-9DA9-138730144F9E Q33338763-66C5DA72-1049-47B0-87D9-9ADAF27CFC37 Q33344377-2DB9430F-AAE6-4084-B0AB-FD78F5EBB6C7 Q33346607-862D728D-0397-4F9C-8A54-3E9E18258900 Q33347614-03A2744E-0C2A-42EC-920D-80EAD33C90A8 Q33363498-7DB175C2-2DAC-47E6-B6BC-8C3A5306596A Q33379565-D48F32DB-AE1A-40AD-B36F-BC3DCFEF4FF5 Q33380135-02BF3AA5-8EE3-47B7-B258-DF2E5E1CD3BC Q33391919-DCFCE87A-CB62-4DD5-91B1-DB31D23333C3 Q33394947-6DCAE028-A0FD-49ED-A708-3970D0C4892F Q33397239-EC70433A-2DDF-4AD4-81C3-49146A060986 Q33401132-69B7C6DB-52CC-4128-BDBD-B1221159FD5D Q33418091-6FC2B482-A4F7-4A5B-9C24-165D369A0C6C Q33438714-21484332-45BF-4B38-8AA6-389D8C41A945

P2860

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

http://www.wikidata.org/entity/Q28140129

description

2000 nî lūn-bûn

@nan

2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Fludarabine compared with chlo ...... r chronic lymphocytic leukemia

@ast

Fludarabine compared with chlo ...... r chronic lymphocytic leukemia

@en

Fludarabine compared with chlo ...... r chronic lymphocytic leukemia

@nl

type

label

Fludarabine compared with chlo ...... r chronic lymphocytic leukemia

@ast

Fludarabine compared with chlo ...... r chronic lymphocytic leukemia

@en

Fludarabine compared with chlo ...... r chronic lymphocytic leukemia

@nl

prefLabel

Fludarabine compared with chlo ...... r chronic lymphocytic leukemia

@ast

Fludarabine compared with chlo ...... r chronic lymphocytic leukemia

@en

Fludarabine compared with chlo ...... r chronic lymphocytic leukemia

@nl

P1433

Q28140129-3EED8AC7-9EE7-41EA-BE28-44531B27DDB1

P1476

Q28140129-C1141961-5EF1-4FD9-BDF6-245C3E5A502C

P2093

Q28140129-1B3D6CA1-EA57-4F91-9CDA-857256F49AFE

Q28140129-2010D7E9-D30D-4BAA-9BA6-30E73338E0FD

Q28140129-2E9BFF8E-6B4E-450E-8116-B0AF2F62B595

Q28140129-3D39F18B-DD5E-4401-809C-54EBBDD6B603

Q28140129-81756554-72F5-4C02-8FC5-7DB2DD195F02

Q28140129-92862D22-2C1F-4F92-824B-FE4EFF63A530

Q28140129-A25BD80A-B2C4-47EC-908F-325B7939FC41

Q28140129-E0D4ED4A-D034-4B7B-8285-822CC77721B5

Q28140129-E757AC0B-2D37-48D7-9179-92A148781A49

Q28140129-EFBFE444-5067-4C24-AF73-A5DDC5A1C2A5

P304

Q28140129-11CAB597-8A94-46D3-A5A5-98CB83B61EC4

P31

Q28140129-F3F7E5A3-2EDB-4C6E-89FA-6D453CFB09B7

P3181

Q28140129-8E216C4A-FB35-420A-AD7E-27B4204A5287

P356

Q28140129-83DB264B-FF2D-48ED-A8E2-9949F201BEB8

P407

Q28140129-2CA4A14B-7A2A-4C31-AA86-07142EC35F3A

P433

Q28140129-CF974D63-3067-41EF-BA2F-42D9A3E56DCA

P478

Q28140129-CA0DA952-5E03-403A-A3F4-B21E71A7A52C

P50

Q28140129-EA1B0B56-05AB-47A7-9186-044D019A27E2

P577

Q28140129-23E91E82-10CD-4D03-A5FE-5C1015280ABC

P698

Q28140129-C6149DA2-D0D1-42EA-A911-138DCDD3E1E2

P921

Q28140129-2B303EF9-7BCB-40DE-ABD8-BC118130AF42

Q28140129-9BC20011-3D6D-42DD-ADCA-32B5F86A4599

P3181

P356

NEJM200012143432402

P1433

The New England Journal of Medicine

P1476

Fludarabine compared with chlo ...... r chronic lymphocytic leukemia

@en

P2093

B D Cheson

http://www.w3.org/2001/XMLSchema#string

B L Peterson

http://www.w3.org/2001/XMLSchema#string

C A Schiffer

http://www.w3.org/2001/XMLSchema#string

G A Threatte

http://www.w3.org/2001/XMLSchema#string

J Hines

http://www.w3.org/2001/XMLSchema#string

J Kolitz

http://www.w3.org/2001/XMLSchema#string

K R Rai

http://www.w3.org/2001/XMLSchema#string

L Elias

http://www.w3.org/2001/XMLSchema#string

L Shepherd

http://www.w3.org/2001/XMLSchema#string

R A Larson

http://www.w3.org/2001/XMLSchema#string

P304

1750-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2170761

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJM200012143432402

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

343

http://www.w3.org/2001/XMLSchema#string

P50

Frederick R. Appelbaum

P577

2000-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11114313

http://www.w3.org/2001/XMLSchema#string

P921